No Love for Antibiotics From the FDA (WYE.DL)

No Love for Antibiotics From the FDA

Wyeth (NYSE: WYE ) was on a roll with the FDA, getting three approvals in the first four months of the year, but its latest letter from the FDA didn't quite have the same happy vibe.

The drugmaker received an approvable letter for its antibiotic Tygacil as a treatment for patients with community-acquired pneumonia (CAP). Tygacil is already approved to kill the microbes causing complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) in patients.

Using typical pharmaspeak, Wyeth said the FDA had a problem with the safety and efficacy of the data, but didn't really say what additional information the FDA needs, nor how long it would take to submit a response to the approvable letter.

In addition to the undisclosed issues, Wyeth said that the FDA is also worried about the liver toxicity that Tygacil may cause, and it wants more information about whether the benefits of the antibiotic outweigh the risks. Wyeth turned in what it believes is an answer to the agency's issues, but the FDA has yet to review it.

The FDA has been particularly hard on anti-infective drugs recently. Theravance (Nasdaq: THRX ) had its FDA advisory committee meeting cancelled after the FDA decided it needed more time to review issues at different sites that performed its phase 3 clinical trial used to support the marketing application for its antibiotic Telavancin. Johnson & Johnson (NYSE: JNJ ) also got an approvable letter for its antibiotic Ceftobiprole recently.

Johnson & Johnson has an upcoming advisory committee meeting to expand the use of Doribax into patients with hospital-acquired pneumonia. The way the FDA has been going lately, the company should probably be happy that it got Doribax approved to treat intra-abdominal infections and complicated urinary tract infections before the FDA seemingly tightened up the standards for approving antibiotics.

Given the state of the FDA, I wouldn't hold my breath while Wyeth gets things cleared up and a response resubmitted to the FDA -- it could be a while.

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

Johnson & Johnson is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.